FI924982L - Frystorkat preparat som innehaoller monoklonal motkropp - Google Patents

Frystorkat preparat som innehaoller monoklonal motkropp Download PDF

Info

Publication number
FI924982L
FI924982L FI924982A FI924982A FI924982L FI 924982 L FI924982 L FI 924982L FI 924982 A FI924982 A FI 924982A FI 924982 A FI924982 A FI 924982A FI 924982 L FI924982 L FI 924982L
Authority
FI
Finland
Prior art keywords
motkropp
frystorkat
preparat
monoclonal
som innehaoller
Prior art date
Application number
FI924982A
Other languages
English (en)
Finnish (fi)
Other versions
FI924982A7 (fi
FI924982A0 (fi
Inventor
Tamotsu Fukuda
Yukio Shimazaki
Yasuyuki Kuroiwa
Shiro Takagi
Original Assignee
Mitsui Toatsu Chemicals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12663510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI924982(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsui Toatsu Chemicals filed Critical Mitsui Toatsu Chemicals
Publication of FI924982A7 publication Critical patent/FI924982A7/fi
Publication of FI924982A0 publication Critical patent/FI924982A0/fi
Publication of FI924982L publication Critical patent/FI924982L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI924982A 1991-03-08 1992-02-28 Frystorkat preparat som innehaoller monoklonal motkropp FI924982L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4343191 1991-03-08
PCT/JP1992/000226 WO1992015331A1 (en) 1991-03-08 1992-02-28 Lyophilized monoclonal antibody preparation

Publications (3)

Publication Number Publication Date
FI924982A7 FI924982A7 (fi) 1992-11-04
FI924982A0 FI924982A0 (fi) 1992-11-04
FI924982L true FI924982L (fi) 1992-11-04

Family

ID=12663510

Family Applications (1)

Application Number Title Priority Date Filing Date
FI924982A FI924982L (fi) 1991-03-08 1992-02-28 Frystorkat preparat som innehaoller monoklonal motkropp

Country Status (10)

Country Link
US (1) US5908826A (enExample)
EP (2) EP0841067B1 (enExample)
JP (1) JPH0565233A (enExample)
AU (1) AU645187B2 (enExample)
CA (1) CA2082169A1 (enExample)
DE (2) DE69232617T2 (enExample)
DK (2) DK0841067T3 (enExample)
FI (1) FI924982L (enExample)
NO (1) NO924279D0 (enExample)
WO (1) WO1992015331A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP2275119B1 (en) * 1995-07-27 2013-09-25 Genentech, Inc. Stable isotonic lyophilized protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方
JP3624543B2 (ja) * 1996-05-02 2005-03-02 東ソー株式会社 免疫反応試薬及びその製造方法
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
WO1999037329A1 (en) * 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6750330B1 (en) * 1998-05-14 2004-06-15 Ashley Davis Lyophilized tubulins
EP1254666A4 (en) * 1999-12-28 2004-12-22 Chugai Pharmaceutical Co Ltd STABLE ANTIBODY COMPOSITIONS AND INJECTION FORMULATIONS
US20040038878A1 (en) * 2000-08-04 2004-02-26 Masahiko Tanikawa Injectable protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20030113316A1 (en) * 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
ATE480567T1 (de) 2003-04-04 2010-09-15 Genentech Inc Hochkonzentrierter antikörper und proteinformulierungen
JP5452835B2 (ja) 2003-07-15 2014-03-26 中外製薬株式会社 形質転換細胞によるＩｇＭの産生とその定量方法
PL1698640T5 (pl) * 2003-10-01 2019-12-31 Kyowa Hakko Kirin Co., Ltd. Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworu
US7803914B2 (en) 2003-10-09 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for stabilizing protein solutions
JP4762717B2 (ja) * 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
US20070184050A1 (en) * 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
MX2007014148A (es) * 2005-05-19 2008-01-11 Amgen Inc Composiciones y metodos para incrementar la estabilidad de anticuerpos.
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
MX2009003635A (es) * 2006-10-06 2009-04-22 Amgen Inc Formulaciones de anticuerpos estables.
CA2666492C (en) * 2006-10-20 2012-07-17 Douglas Rehder Stable polypeptide formulations
US20100260766A1 (en) * 2007-03-22 2010-10-14 Arvind Srivastava Stable antibody formulations
JP5322405B2 (ja) * 2007-06-07 2013-10-23 小林製薬株式会社 タンパク質含有組成物
US8318161B2 (en) 2009-03-06 2012-11-27 Genentech, Inc. Anti-oxidized LDL antibody formulation
BR112012022258A2 (pt) 2010-03-01 2016-10-25 Bayer Healthcare Llc anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi)
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
CA3116725C (en) 2010-11-05 2023-10-24 Novartis Ag Secukinumab for use in the treatment of psoriatic arthritis
RS55385B1 (sr) 2010-11-11 2017-03-31 Abbvie Biotechnology Ltd Tečna formulacija anti-tnfalfa antitela visoke koncentracije
JP2012158615A (ja) * 2012-05-28 2012-08-23 Kobayashi Pharmaceutical Co Ltd 還元糖によるタンパク質変性を抑制する方法
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
WO2015181633A2 (en) 2014-04-11 2015-12-03 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
US20170231995A1 (en) 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
ES2995985T3 (en) 2015-08-13 2025-02-11 Amgen Inc Charged depth filtration of antigen-binding proteins
CN108602827B (zh) 2015-11-06 2021-08-20 安塞塔制药公司 Bruton酪氨酸激酶的咪唑并吡嗪抑制剂
US20240417445A1 (en) * 2023-06-13 2024-12-19 Grifols Worldwide Operations Limited Method for producing a lyophilized composition comprising polyclonal igm and composition obtained

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2149304A (en) * 1936-04-20 1939-03-07 Sharp & Dohme Inc Lyophilic biologically active substances
SU700132A1 (ru) * 1978-06-30 1979-11-30 Томский Ордена Трудового Красного Знамени Научно-Исследовательский Институт Вакцин И Сывороток Способ получени сухого препарата иммуноглобулина
JPS57140724A (en) * 1981-02-25 1982-08-31 Green Cross Corp:The Heat-treatment of aqueous solution containing cold insoluble globulin
JPS58167518A (ja) * 1982-03-29 1983-10-03 Nippon Sekijiyuujishiya ゼラチン誘導体添加静注用人免疫グロブリンの製造法
JPS6035263A (ja) * 1983-08-05 1985-02-23 Wako Pure Chem Ind Ltd 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬
JPS60146833A (ja) * 1984-01-10 1985-08-02 Green Cross Corp:The モノクロ−ナル抗体製剤
JP2565303B2 (ja) * 1984-05-25 1996-12-18 三井東圧化学株式会社 緑膿菌感染症の予防治療剤
US4650772A (en) * 1984-08-09 1987-03-17 Abbott Laboratories Monoclonal antibody stabilization
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPS61176532A (ja) * 1985-01-30 1986-08-08 Green Cross Corp:The プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPH0825903B2 (ja) * 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
JPS6178731A (ja) * 1985-05-20 1986-04-22 Green Cross Corp:The 加熱処理免疫グロブリン製剤
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
JPS6388197A (ja) * 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
EP0327648B1 (en) * 1986-12-15 1993-06-09 MITSUI TOATSU CHEMICALS, Inc. Human monoclonal antibody and drug for prophylaxis and treatment of infectious diseases comprising same as effective ingredient
EP0303088B1 (en) * 1987-08-10 1992-11-11 Miles Inc. Purified igm
WO1989011298A1 (en) * 1988-05-27 1989-11-30 Centocor, Inc. Formulation for antibody reagents
CA2049342A1 (en) * 1989-03-27 1990-09-28 Sally Bolmer Formulations for stabilizing of igm antibodies
JPH0384461A (ja) * 1989-08-28 1991-04-10 Green Cross Corp:The 免疫学的凝集反応試薬及びその製法
JPH0911350A (ja) * 1995-06-30 1997-01-14 Olympus Optical Co Ltd エネルギー硬化型樹脂を用いた光学素子の製造方法

Also Published As

Publication number Publication date
FI924982A7 (fi) 1992-11-04
DE69225757T2 (de) 1998-12-03
DK0841067T3 (da) 2002-07-15
AU645187B2 (en) 1994-01-06
FI924982A0 (fi) 1992-11-04
JPH0565233A (ja) 1993-03-19
DK0531539T3 (da) 1998-10-12
CA2082169A1 (en) 1992-09-09
NO924279L (no) 1992-11-06
EP0531539B1 (en) 1998-06-03
US5908826A (en) 1999-06-01
DE69232617T2 (de) 2002-10-31
NO924279D0 (no) 1992-11-06
EP0841067B1 (en) 2002-05-22
EP0531539A1 (en) 1993-03-17
WO1992015331A1 (en) 1992-09-17
EP0531539A4 (enExample) 1995-04-05
AU1337592A (en) 1992-10-06
EP0841067A1 (en) 1998-05-13
DE69225757D1 (de) 1998-07-09
DE69232617D1 (de) 2002-06-27

Similar Documents

Publication Publication Date Title
FI924982L (fi) Frystorkat preparat som innehaoller monoklonal motkropp
FI930836L (fi) Topiska preparat som innehaoller cyklosporin
FI924091A7 (fi) Autoriseringsprotokoll som foersiktighetshjaelpmedel
FI933167A0 (fi) N-alkylkinuklidiniumsalter som substans-p antagonister
FI921675L (fi) En detergentsammansaettning innehaollande polyimidbiopolymer som blir hydrolyserad i tvaettningsvatten
FI921556L (fi) Plasttillslutning som visar otillboerlig anvaendning
FI921182L (fi) Velangummi som snabbt hydratiseras
FI935842A7 (fi) Anvaendning av tetrahydrokarbazonderivat som 5ht1 -reseptoragonister
FI921901L (fi) Haorshampookomposition som ger foerbaettrad haorkonditioneringsegenskaper
FI924505A7 (fi) Direktbehandling av metall som renats genom elektrisk slaggsmaeltning
FI924553L (fi) Tiofensulfonamider anvaendbara som kolanhydrasinhibitorer
FI924865A7 (fi) Tablettutdelare som uppvisar laosmedel
FI930991L (fi) Polymerer som innehaoller diesterenheter
FI931111A0 (fi) Staongtvaolskompositioner som innehaoller sackaros
FI923364A7 (fi) Foerfarande foer framstaellning av en farmaceutisk sammansaettning som paoverkar det retikuloendotela systemet
FI935351L (fi) Transdelmalt administrerbara preparat innehaollande medetomidin
FI935944L (fi) Pyratsolopyrimidin- samt pyrimidinylbisfosfonestrar som anti- inflammatorer
FI925330L (fi) Substituerade fenylfenoler som leukotrienantagonister
FI924306L (fi) Foerbaettrat vaevnadslim som framstaellts genom anvaendning av kryofaellning
FI924571L (fi) Foerfarande foer binaer kodning av punkter i en punktgrupp som anvaends i multibaervaogsmodulering av ofdm-typ
FI933022A0 (fi) Radiosystem som bildar en traodloes lokalslinga
FI922743A0 (fi) Preparat.
FI924034L (fi) Preparat foer foerbaettrande av haorvaext
MX9200123A (es) Pandereta
FI920190A0 (fi) Paostrykbart preparat foer applicering av maskmedel.

Legal Events

Date Code Title Description
FD Application lapsed